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A major hurdle in using complex systems for drug
screening is the difficulty of defining the mechanistic
targets of small molecules. The zebrafish provides an
excellent model system for juxtaposing develop-
mental phenotypes with mechanism discovery using
organism genetics. We carried out a phenotype-
based screen of uncharacterized small molecules in
zebrafish that produced a variety of chemically
induced phenotypes with potential genetic parallels.
Specifically, kalihinol F caused an undulated noto-
chord, defects in pigment formation, hematopoiesis,
and neural development. These phenotypes were
strikingly similar to the zebrafish mutant, calamity,
an established model of copper deficiency. Further
studies into the mechanism of action of kalihinol F
revealed a copper-chelating activity. Our data sup-
port this mechanism of action for kalihinol F and
the utility of zebrafish as an effective system for iden-
tifying therapeutic and target pathways.
INTRODUCTION
Amajor challenge in the drug discovery process often centers on
assigning in vivo activity to candidate compounds. As a potential
solution, zebrafish have proven useful for determining both
genetic and molecular mechanisms and may offer a powerful
tool for understanding drug mechanisms (Kaufman et al., 2009;
Taylor et al., 2010; Zon and Peterson, 2005). Small embryo
size and high fecundity of adult females make zebrafish
amenable to moderate throughput screening and enable
screens that directly affect a specific phenotype. Rapid zebrafish
development that occurs ex utero, combined with optical trans-
parency of the embryos, allow for convenient observation of
morphologic changes with a dissecting microscope without
sacrificing the embryo (Kimmel et al., 1995). Small molecule
screening in a whole organism also provides a physiologicChemistry & Biology 20,context that is lacking in cell-based and in vitro assays and
affords preliminary toxicity, tissue specificity, and pharmacoki-
netic profiles that greatly facilitate lead compound identification
and optimization. Most importantly, the zebrafish is a vertebrate
system that shares a high degree of genetic and physiologic sim-
ilarity to humans. Numerous zebrafish genetic mutants have
been established that faithfully phenocopy human disease
mechanisms and zebrafish-based chemical genetic screens
are currently underway to identify compounds that modify dis-
ease phenotypes, an approach that promotes development of
novel biologic tools and therapeutics (Ingham, 2009; Kaufman
et al., 2009; Lieschke and Currie, 2007; MacRae and Peterson,
2003; Shin and Fishman, 2002; Taylor et al., 2010; Zon and
Peterson, 2005).
Previous efforts have clearly demonstrated the utility of zebra-
fish in identifying compounds that affect specific developmental
phenotypes. In 2000, Peterson and colleagues carried out one of
the earliest zebrafish-based chemical screens and discovered
small molecules that perturb normal development of the CNS,
cardiovascular system, pigmentation, and ear (Peterson et al.,
2000). Since then, numerous screens have revealed chemical
modifiers of zebrafish embryonic development (Kaufman et al.,
2009; Taylor et al., 2010). However, another approach may exist
to use zebrafish to define mechanisms of uncharacterized com-
pounds and compound collections. For example, the kalihinol
family of compounds are isonitrile diterpenoids originally isolated
from the marine sponge Acanthella sp. (Patra et al., 1984). These
compounds are characterized by a biflorane carbon skeleton
and show a variety of biologic activities that include antibacterial,
antifungal, antiparasitic, antifouling, and cytotoxicity against
tumor cells (Alvi et al., 1991; Chang et al., 1984; Fusetani et al.,
1990; Hirota et al., 1996; Miyaoka et al., 1998; Omar et al.,
1988; Sun et al., 2009; Wolf and Schmitz, 1998). Although spe-
cific kalihinols, such as kalihinol F, have proposed mechanisms
in bacteria and starfish, it is not clear how kalihinols might func-
tion within a vertebrate system both from physiologic and mech-
anistic points of view (Bugni et al., 2004; Ohta et al., 2003).
In this study, we performed a zebrafish-based phenotypic
screen of 954 diverse compounds and juxtaposed the observed
chemically induced phenotypes with known genetic mutations.
This analysis led us to focus on kalihinol F, which produced a753–763, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 753
Figure 1. Zebrafish-Based Chemical Screen Leads to Identification of Interesting Phenotypes
(A) Schematic of the zebrafish phenotype screen. Wild-type embryos were arrayed in 96-well plates and treated with 10 mM or 25 mg/ml of test compounds
at 7 hpf. Phenotypes were scored at 32 hpf.
(B) Pie chart showing phenotype distribution from the zebrafish screen.
(C) At 32 hpf, zebrafish embryos have a defined head, body, and tail, with a prominent yolk (C, DMSO). Normal-looking embryos were observed for 743 com-
pounds (C1–C3), 119 were toxic to embryos (C11–14), and 92 had viable phenotypes (C4–C10) that include edema (red arrow), underdeveloped head (black
arrow), yolk (orange arrow), and tail/body (blue arrow) malformations.
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Kalihinol F Is a Copper Chelatorwavy notochord, loss of pigmentation, as well as hematologic
and neurologic abnormalities. The kalihinol F-induced pheno-
types were highly similar to those reported for the zebrafish
mutant calamity (cal), which shows evidence of copper defi-
ciency due to a mutation in the copper transporter, atp7a (Men-
delsohn et al., 2006). Consistent with reduced copper levels,
kalihinol F-induced phenotypes were prevented with exogenous
copper. Further studies demonstrate that kalihinol F chelates
copper, an activity shared by other kalihinol analogs. Overall,
our findings support this mechanism of action for kalihinol F
and demonstrate the use of zebrafish as an effective system
for integrating biologic activity with mechanism of action.
RESULTS
A Zebrafish-Based Phenotypic Screen Identifies a Small
Molecule Inducing a Copper-Deficient Phenotype
We utilized wild-type zebrafish embryos to screen for bioactive
small molecules. For our phenotypic assay, we arrayed 7 hr post-
fertilization (hpf) embryos in 96-well plates at one embryo per
well, treated with test compounds and visually evaluated devel-
opmental phenotypes at 32 hpf (Figure 1A). A total of 954 com-
pounds from different chemical libraries were used in the screen
and included synthetic drug-like compounds, US Food and Drug754 Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 ElsevierAdministration-approved drugs, and natural products (Fig-
ure 1B). No discernible effect was observed for the majority of
the compounds, resulting in normal-appearing embryos with
well-defined body structures at 32 hpf (Figures 1B and 1C,
dimethyl sulfoxide [DMSO], c1–c3). Of the active compounds,
119 caused overt lethality (Figures 1B and 1C, c11–c14) while
92 had viable phenotypes that showed varying developmental
defects (Figures 1B and 1C, c4–c10). A systematic search of
phenotypes elicited by our compound collection against known
zebrafish genetic mutants resulted in an interesting match with
the zebrafish mutant calamity (cal). The calamity mutant carries
a mutation in the ubiquitous copper transporter gene atp7a
and displays copper deficiency-induced developmental defects
(Mendelsohn et al., 2006). Kalihinol F-treated embryos caused
defects consistent with copper deficiency (Figures 2B–2D).
Kalihinol F (Figure 2A) is amarine natural product that has been
reported to have antibiotic and cytotoxic activities (Alvi et al.,
1991; Bugni et al., 2004; Chang et al., 1984; Fusetani
et al., 1990; Hirota et al., 1996; Miyaoka et al., 1998; Ohta
et al., 2003; Omar et al., 1988; Sun et al., 2009;Wolf and Schmitz,
1998). It has not, however, been associated with copper homeo-
stasis. At 32 hpf, embryos treated with 2.5 mg/ml kalihinol F had
an undulated notochord, as confirmed by in situ staining for ntl,
and a complete absence of pigmentation (Figures 2B–2D). In situLtd All rights reserved
Figure 2. Embryos Treated with Kalihinol F Show a Phenotype Consistent with Copper Deficiency
(A) Chemical structure of kalihinol F.
(B) Exposure of zebrafish embryos to 2.5 mg/ml of kalihinol F (kal F) resulted in a wavy notochord (black arrow, D, ntl), loss of pigmentation (blue arrow) and
enlarged hindbrain vesicle (green arrow) as compared to DMSO-treated control embryos. Boxed figures are enlargements of highlighted portions on whole
embryos.
(C) o-dianisidine staining at 72 hpf revealed loss of hematopoiesis (red arrows) in treated embryos versus control.
(D) In situ hybridization on 32 hpf embryos for ntl, myod, and hnf6. not, notochord; som, somites; and sc, spinal cord.
(E) In situ hybridization for hbae1, hbbe1, hbbe3, alas2, atoh7, col8a1a, and col9a1 confirms gene expression analysis by RNA sequencing that is consistent with
copper-deficient phenotype of kalihinol F.
See also Tables S1 and S2.
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Table 1. GO Analysis of the Differentially Regulated Genes in
Kalihinol F-Treated Embryos
GO Category
Total
Genes
Changed
Genes Enrichment FDR
Hemoglobin complex 15 8 51.6 0
Oxygen transport 27 8 28.7 0
Oxygen binding 40 9 21.8 0
Heme binding 156 13 8.1 0
Extracellular region 1,430 47 3.2 0
Response to
mineralocorticoid
stimulus
31 5 15.6 0.001
Inflammatory response 254 12 4.6 0.002
Response to chemical
stimulus
2,073 40 1.9 0.006
Organic ether metabolic
process
96 7 7.1 0.007
Notochord
development
45 5 10.7 0.007
Fibronectin binding 11 3 26.4 0.011
Immune response 548 16 2.8 0.011
Response to
progesterone stimulus
31 4 12.5 0.018
Ossification 165 8 4.7 0.020
Regulation of
angiogenesis
91 6 6.4 0.020
Lipoprotein metabolic
process
96 6 6.0 0.025
Eukaryotic cell surface
binding
15 3 19.3 0.025
Triglyceride metabolic
process
66 5 7.3 0.031
Vesicle lumen 38 4 10.2 0.032
Protein activation
cascade
40 4 9.7 0.035
Cartilage development 151 7 4.5 0.043
Protein maturation 111 6 5.2 0.043
Response to other
organism
401 12 2.9 0.044
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Kalihinol F Is a Copper Chelatorstaining for myoD and hnf6 also revealed short, deformed
somites and wavy spinal cord, respectively (Figure 2D). By
56 hpf, loss of pigmentation was more evident. The embryos
also appeared curved and had a slow heart beat with no circula-
tion (Figure 2B). The phenotype became progressively worse by
72 hpf, as evidenced by an enlarged hindbrain vesicle, edema,
severe body malformation, and crinkly tail (Figure 2B). Loss of
blood was confirmed by o-dianisidine staining (Figure 2C).
To confirm the bioactivity of kalihinol F at the molecular level,
we looked at the gene expression profile of kalihinol F-treated
embryos with RNA sequencing. We found that the differentially
expressed genes in treated embryos, some of which we
confirmed by in situ hybridization, reflected the morphologic
defects that we have previously associated with kalihinol F
and copper deficiency (Table 1; Figure 2E; Tables S1 and S2
available online). Downregulation was observed for hemoglobin756 Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 Elseviergenes such as hbae1, hbbe2, hbae3, hbbe1, hbaa1, and hbbe3
that are involved in oxygen transport, heme binding, and forma-
tion of the hemoglobin complex. Several genes that are
expressed in the brain, eye, and blood were also downregulated.
Kalihinol F-treated embryos exhibited increased expression of
inflammatory and immune response genes, as well as col8a1a
and col9a1, genes that are both essential for normal notochord
and cartilage development and consistent with previous studies
reporting elevated collagen levels during copper deficiency
(Gansner et al., 2007; Tilton et al., 2006).
Exogenous Copper Prevents Kalihinol F
Copper-Deficient Phenotype
Because kalihinol F-treated embryos phenocopy cal, we
hypothesized that kalihinol F might be inducing copper defi-
ciency either by targeting atp7a, resulting in impaired cellular
uptake of copper or by reducing overall levels of bioavailable
copper for normal growth and development through copper
chelation. To distinguish between the two, treated embryos
were given exogenous copper, which will reverse copper chela-
tion but will not overcome defective copper absorption due to
inactivated atp7a, as previously shown (Mendelsohn et al.,
2006). Exposure of treated embryos to 10 mM CuCl2 led to a
complete prevention of the kalihinol F phenotype (93%,
n = 120). The notochord appeared normal, as did the somites
and spinal cord (Figures 3A and 3B). Normal pigmentation
returned and healthy blood circulation was observed (Figures
3A and 3B). To evaluate specificity for copper rescue, embryos
were also given zinc and calcium, both +2 metals. Neither zinc
(100%, n = 82) nor calcium (100%, n = 27) were capable of
reverting any of the kalihinol F-induced embryo defects (Figures
3A and 3B; Figure S1).
Kalihinol F Chelates Copper
Based on the phenotype and copper prevention experiments,
our data suggest that kalihinol F might act as a copper chelator.
To investigate this further, we performed a modified BCA assay
to assess the copper-chelating ability of kalihinol F in compari-
son with several controls. A constant concentration of CuCl2
was mixed with various concentrations of each of kalihinol F,
b-aminopropionitrile (b-APN), and the positive controls EDTA
and trientine HCl (T-HCl), a copper chelator used in the clinic
to treat Wilson disease (Ding et al., 2011). As expected, a
decrease in absorbance due to free copper was observed with
increasing concentrations of EDTA and T-HCl (Figure 4A). At
2-fold molar excess, copper was almost completely chelated.
A similar behavior was displayed by kalihinol F; there was a
reduction in absorbance that was concentration-dependent,
although not as steep as that seen with EDTA and T-HCl. The
lysyl oxidase inhibitor b-APN did not exhibit any copper chelating
activity (Figure 4A).
To further validate the mode of action of kalihinol F, we turned
to yeast, whose growth in respiratory-selective media is depen-
dent on copper, a cofactor for Cox1 and Cox2, which are essen-
tial for respiration (Weintraub and Wharton, 1981). Wild-type
yeast cells grown in glycerol-lactate media supplemented with
either kalihinol F or with the known copper chelator, bathocu-
proine disulphonate (BCS), showed a dose-dependent growth
inhibition that was rescued with exogenous copper, but notLtd All rights reserved
Figure 3. Kalihinol F Phenotype Is Prevented by Addition of Copper
(A) Five hr postfertilization embryos were treated with either DMSO or 2.5 mg/ml kal F then rescued at 7 hpf with 10 mMCuCl2, Zn(OAc)2 and embryo water (e H2O).
Only copper-treated embryos showed normal pigmentation, notochord, and hindbrain comparable to control embryos (bottom row, second and fourth figures
from left).
(B) Normal hematopoiesis and rescue of notochord, somites, spinal cord with copper were confirmed by o-dianisidine staining and in situ for ntl,myod, and hnf6.
See also Figure S1.
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tion on copper (Figure 4B).
Because of its paramagnetic nature, copper (II) causes broad-
ening of resonance signals in nuclearmagnetic resonance (NMR)
spectroscopy as a result of distance-dependent paramagnetic
relaxation enhancement (PRE) of nuclear spins (Bloembergen,
1957; Solomon, 1955). To confirm the interactions between
kalihinol F and copper by NMR, a titration experiment was per-
formed to measure the effects of addition of CuCl2 on the spec-
tral line widths of kalihinol F in DMSO-d6. Kalihinol F was present
at 11 mM and NMR spectra were collected at the titration end
points 0.00, 0.05, 0.10, 0.15, 0.20, 0.30, 0.40, and 0.50 mole
equivalents of CuCl2 in D2O. There was a difference among the
signals in the degree of line broadening that occurred in
response to copper addition. Some signals exhibited a more
rapid onset and more extensive degree of broadening as the
titration progressed. The signal for H-5, in particular, was
strongly broadened at 0.05 eq Cu (II) and had essentially merged
with the baseline by 0.30 eq Cu (II) (Figures 2A and 4C). In addi-
tion, the center frequency for H-5 gradually moved upfield as theChemistry & Biology 20,titration progressed. Before the addition of Cu (II), dH-5 occurred
at 4.26 ppm. The frequency shifted by 0.03 ppm upfield for each
addition of 0.05 eq Cu (II). The remaining signals also exhibited
increased broadening as the titration progressed, but did so to
a much lesser extent than H-5 (Figure 4C). The remaining signals
also displayed smaller shifts in frequency than H-5. Overall,
these results suggest that kalihinol F does bind to Cu (II) in
DMSO and that the binding site is likely near H-5.
Bioactivity for the Kalihinol Family of Compounds
Kalihinols belong to a large family of multifunctional diterpenes
that exhibit a wide array of biologic properties (Alvi et al., 1991;
Bugni et al., 2004; Chang et al., 1984; Fusetani et al., 1990; Hirota
et al., 1996; Miyaoka et al., 1998; Ohta et al., 2003; Omar et al.,
1988; Sun et al., 2009; Wolf and Schmitz, 1998). To investigate
whether the copper-chelating activity is shared by other kalihi-
nol analogs, 7 hpf embryos were treated with six additional kali-
hinol compounds with DMSO as control (Figure 5A). Kalihinol X
(100%, n = 50), kalihinol A (99%, n = 75), kalihene (95%,
n = 141), and kalihinol G (100%, n = 149) exhibited a similar753–763, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 757
Figure 4. Kalihinol F Is a Copper Chelator
(A) BCA assay was performed on 5mMCuCl2 supplemented with EDTA, T-HCl, b-APN, or kal F, in increasing molar excess. Copper chelation was determined by
measuring absorbance at 562 nm. Graph shown above is representative of multiple experiments. Values indicate mean ± SD.
(B) Wild-type W303 yeast cells were grown on YP-agar plate containing respiration-selective media treated with DMSO, BCS or kal F. Growth inhibition due to
limiting copper levels was evaluated visually. Addition of copper, but not iron, was able to rescue yeast growth (lanes 3 and 4). Picture shown above is repre-
sentative of multiple experiments.
(C) Effects of addition of Cu2+ to the 1H NMR line widths of H-5 (left panel) and the methyl group signals (right panel) of kalihinol F.
(D) Proposed binding site of copper based on previously determined X-ray structure of kalihinol F (Patra et al., 1984). Note that the isonitrile groups attached to
C-5 and C-15 are oriented toward the same face of the molecule and potentially forms a bidentate coordination site for Cu2+ as depicted. Note also the proximity
of H-5 and the furan ether group.
See also Figure S3.
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Kalihinol F Is a Copper Chelatorcopper-deficient phenotype at 2.5 mg/ml (Figure 5B). Pulcherri-
mol (95%, n = 107) only showed activity at a higher concentration
of 25 mg/ml and this was reflected in the NMR analysis of
the interaction between pulcherrimol and copper (Figures 5B
and 5C). When a second titration was carried out on a sample
containing pulcherrimol, the onset of line broadening was less
extensive for pulcherrimol compared to kalihinol F, which sug-
gests a weaker affinity of pulcherrimol for Cu (II) (Figures 4C
and 5C). Kalihinol Y (100%, n = 48), was not active at all (Fig-
ure 5B). As previously observed with kalihinol F, the copper-defi-
cient phenotype induced by the kalihinol analogs was prevented
by treatment with copper (Figure 5B).
Kalihinol F Mitigates Toxicity Associated with
Overexposure to Copper
Copper chelation therapy has long been used to treatWilson dis-
ease (WD), a disorder characterized by hepatic accumulation of
copper due to mutations in ATP7b, a liver-specific copper trans-
porter (Huster, 2010). To determine if kalihinol F can prevent the
harmful effects of excess copper, 5 hpf embryos were given
5 mM CuCl2 and were further treated with 5 mg/ml kalihinol F or
10 mM T-HCl. At 72 hpf, embryos exposed to copper remained
in their chorion. They appeared shorter and exhibited growth758 Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 Elsevierdefects that include a pinched yolk extension (96%, n = 142)
and a smaller head, as confirmed by in situ for fabp7 (95%,
n = 48, Figure 6A). In situ hybridization for crx and tfa also
revealed smaller eyes (100%, n = 52) and liver (91%, n = 74),
respectively (Figure 6A). Treatment with kalihinol F reversed
the developmental defects associated with copper toxicity.
The rescued embryos were indistinguishable from control
embryos with normal yolk extension (100%, n = 102) and well-
developed head (100%, n = 42), eyes (100%, n = 50), and liver
(91%, n = 55, Figure 6A). Similar results were observed for
T-HCl (Figure 6A).
To determine if kalihinol F can overcome the toxic effects of
copper in liver cells, human hepatocarcinoma cells (HepG2)
were treated with 80 mM CuCl2 and then rescued with
30 mg/ml kalihinol F or 160 mM T-HCl. Quantitative RT-PCR
was done to evaluate gene expression changes associated
with chemical treatments over 24 hr. Consistent with previous
studies by Muller and colleagues, HepG2 cells incubated with
copper showed reduced expression ofCOMMD1 andCOMMD2
while metallothioneins such as MT1B,MT1E,MT1F, and MT2A,
along with HMOX and heat shock proteins, HSPA1B and
HSPCA, were significantly upregulated (Figure 6B; Muller
et al., 2007). Further treatment with either kalihinol F or T-HClLtd All rights reserved
Figure 5. Other Members of the Kalihinol Family also Show Copper Chelating Activity
(A) Chemical structure of kalihinol analogs.
(B) Seven hr postfertilization embryos were treated with either 25 mg/ml or 2.5 mg/ml of kalihinol analogs and DMSO vehicle control (first, second, and third
columns). For phenotype rescue experiments, 5 hpf embryos were treated with kalihinols and given CuCl2 at 7 hpf (fourth, fifth, and sixth columns). Embryos were
monitored for wavy notochord (black arrow), loss of pigmentation (blue arrow), and hematopoiesis (red arrow).
(C) Effects of addition of Cu2+ to the 1H NMR line widths of the methyl signal region of pulcherrimol.
Chemistry & Biology
Kalihinol F Is a Copper Chelator
Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 759
Figure 6. Kalihinol F Reverses Adverse
Effects of Copper Toxicity
(A) Five hr postfertilization embryos were treated
with 5 mM CuCl2 and rescued at 7 hpf with either
5 mg/ml kalihinol F or 10 mM T-HCl. Excessive
copper resulted in a smaller embryo with pinched
yolk extension (lane 1, black arrow), small head
(lane 2) and eyes (lane 3), and impaired liver
development (lane 4). In situ hybridization for
fabp7, crx (blue arrow), and tfa (red arrow) revealed
normal head development, eye size and proper
liver formation, respectively, for embryos rescued
with kalihinol F or T-HCl.
(B) Human HepG2 cells were treated with 80 mM
copper and rescuedwith either 30 mg/ml kalihinol F
or 160 mM T-HCl. Quantitative RT-PCR showed
gene expression changes induced by copper were
reversed by either kalihinol F (Cu + kal F) or T-HCl
(Cu + T-HCl). Graph shown above is representative
of at least two experiments. Values represent
mean ± SD.
See also Figure S2 and Table S3.
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more pronounced compared with kalihinol F (Figure 6B). This
could be due to a lower amount of kalihinol F (30 mg/ml
78 mM) given to cells because of a limited supply of the com-
pound. There also was toxicity in HepG2 cells exposed to
copper, as evidenced by floating debris, which was alleviated
in rescued cells (Figure S2).
DISCUSSION
Defining the bioactivity and mechanism of action of small mole-
cules is often a challenge in the development of potential thera-
peutics. We have demonstrated that chemical screening in
zebrafish, coupled with genetic analyses, allows for the evalua-
tion of the biologic effects of active compounds with better
insight into their molecular mechanism. Our data revealed kalihi-
nol F to be a copper chelator, which evoked developmental760 Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 Elsevier Ltd All rights reservedabnormalities similar to the known copper
transport mutant, calamity (cal) (Mendel-
sohn et al., 2006).
Priorworkonkalihinols hasbeen limited
to understanding their bioactivity in non-
vertebrate systems and to date, has
not identified a specificmolecular mecha-
nism (Alvi et al., 1991; Bugni et al., 2004;
Chang et al., 1984; Fusetani et al., 1990;
Hirota et al., 1996; Miyaoka et al., 1998;
Ohta et al., 2003; Omar et al., 1988; Sun
et al., 2009; Wolf and Schmitz, 1998).
Consistent with the phenotype observed
for kalihinol F-treated embryos, our BCA
assay data indicate that kalihinol F can
sequester copper, although not as well
as EDTA or T-HCl, a commonly used
drug in copper chelation therapy against
Wilson disease (Figure 4A; Ding et al.,
2011). Kalihinol F exhibited the sameactivity in yeast, where we exploited the dependency of yeast
cells on copper for growth under respiratory-selective media
(Figure 4B; Weintraub and Wharton, 1981). Utilizing NMR to
detect copper binding with kalihinol F, we found that it displayed
a significant affinity for Cu (II) but did not exhibit the tightness of
binding seen with b-penicillamine, another clinically used copper
chelator (Figure 4C; Figure S3; Ding et al., 2011). Although the
affinity of kalihinol F for Cu (II) is weaker, it is predominantly
hydrophobic and may offer the advantage of being able to
penetrate hydrophobic media and potentially to transport Cu (II)
passively through barriers such as cell membranes. Interestingly,
both T-HCl and b-penicillamine did not result in any phenotype
when given to zebrafish embryos (data not shown).
Based on the previously published X-ray structure of kalihinol
F, we propose that copper sits in a binding pocket in the vicinity
of H-5, formed by the isonitrile groups on C-5 and C-15 (Fig-
ure 4D; Patra et al., 1984). Both H-5 and the tetrahydrofuran
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proximity to each other. Moreover, the isonitrile groups on C-5
andC-15 are both located on the same face of the ring assembly.
The lone-pair electrons on the carbon atoms of these groups are
strong candidates for being involved in coordination to Cu (II),
suggesting that it might be possible for them to form a bidentate
binding site for Cu (II). It is interesting to note, however, that the
inactive analog, kalihinol Y, lacks the C-15 isonitrile group, which
suggests that the C-5 isonitrile moiety is critical for copper bind-
ing (Figures 5A and 5B). This is consistent with the effect of
copper on H-5, as seen in our NMR data (Figure 4C).The other
isonitrile on C-10 is located equatorially and is, therefore, not
capable of intramolecularly coordinating a Cu (II) atom at the pro-
posed binding site (Figure 4). In the X-ray structure of kalihinol F,
the isonitrile groups at C-5 and C-15 are roughly parallel to one
another and 4.1 A˚ apart, which would not be a favorable geom-
etry for binding to the same Cu (II) atom. However, a slight rota-
tion around the C-7/C-11 bond and/or theC-14/C-15 bond could
yield a more favorable binding site. Such a rotation could also
change the magnetic environment near H-5, accounting for the
strong perturbation in its chemical shift and its line width.
The differences in the bioactivity of the kalihinol compounds
that we additionally screened revealed functionalities that may
be important for copper chelation (Figure 5). In comparing the
structural differences among the kalihinol analogs, our data indi-
cate the significance of the substituted tetrahydropyranyl/tetra-
hydrofuranyl moiety and the cyano functional group at C-11
and C-10, respectively. Further studies are needed to examine
how the cyano group at C-10 contributes to the overall stability
of the copper-kalihinol complex, despite its distance from the
proposed binding site on the molecule.
Copper is an essential mineral for normal growth and develop-
ment of living organisms. It is an important cofactor for a number
of metabolic enzymes involved in cellular respiration, energy
metabolism, collagen cross-linking, antioxidation, and pigment
formation, among others (Tisato et al., 2010). Copper homeosta-
sis is tightly regulated, as evidenced by human ailments resulting
from unbalanced copper levels (Tisato et al., 2010). Wilson
disease (WD), characterized by copper accumulation in the liver
and marked by neurodegenerative symptoms and hepatotoxic-
ity, is a genetic disease caused by mutations in ATP7B, an
ATPase copper-transporting enzyme that is primarily respon-
sible for copper elimination in the liver (Huster, 2010). Copper
chelation therapy has been a successful treatment strategy for
WD, however, the spectrum of chelators available are limited
and harbor some toxicities (Ding et al., 2011; Huster, 2010;
Tisato et al., 2010; Tu¨mer and Møller, 2010). The ability of
kalihinol F to reverse copper toxicity in zebrafish embryos and
human HepG2 cells to a similar extent as T-HCl, suggests that
kalihinols may have clinical relevance as copper chelators
(Figures 6A and 6B).
The copper-chelating activity exhibited by kalihinols is consis-
tent with a large body of literature reporting isonitrile/isocyanide
compounds interacting with copper and cuproenzymes (Liu and
Reiser, 2011; Reedy et al., 1995; Rhames et al., 2001). One of the
most recent is a report by Zhang and colleagues, where they
show that an isocyanide antifouling compound, Isocyanide 1,
caused a wavy notochord in zebrafish embryos and phenocop-
ied copper deficiency (Zhang et al., 2012). The discovery ofChemistry & Biology 20,kalihinols as copper chelators might aid in identifying potential
binding partners responsible for the wide array of biologic activ-
ity reported for these compounds.
In conclusion, we used zebrafish to rapidly assign an activity
andmechanism of action to kalihinol F. Interestingly, a combined
zebrafish-yeast chemical genetic screen undertaken by Ishizaki
and colleagues identified 45 compounds affecting copper meta-
bolism in zebrafish embryos that included reported copper
chelators and the known MEK inhibitor, U0126, revealing a
copper-dependent target pathway for U0126 and further sup-
porting the utility of the zebrafish in elucidating a mechanism of
action of small molecules (Ishizaki et al., 2010). The kalihinol
family of compounds signifies a class of copper chelators that
may be used as a biologic tool to better elucidate the molecular
mechanisms underlying copper homeostasis. Kalihinols may
represent a copper-chelating pharmacophore. However, to
effectively use kalihinols as copper chelators, further studies
are required to fully characterize its binding affinity to copper.
Kalihinol F may not complex copper as strongly as clinically
used copper chelators but preliminary SAR analysis presented
in this study can facilitate in developing more potent, kalihinol-
based copper chelators that are already membrane permeable
and bioavailable.
SIGNIFICANCE
Elucidating the mechanistic action of small molecules is
frequently restricted by the complexities of vertebratemodel
systems. By using an approach of juxtaposing chemically
induced phenotypes from our zebrafish screen to known
genetic zebrafish mutations, we identified kalihinol F and
the kalihinol family as a class of copper chelators. Our find-
ings may lead to the development of more potent copper
chelators that may prove useful in the clinic. We have also
shown the utility of zebrafish as an effective system for
rapidly assigning a mechanism of action to small molecules
that may be used to more efficiently identify therapeutic and
target pathways.
EXPERIMENTAL PROCEDURES
Zebrafish Maintenance
All animal procedures were approved by the Institutional Animal Care and Use
Committee at the University of Utah. Wild-type Danio rerio (zebrafish) were
maintained as previously described (Westerfield, 1995). Fertilized embryos
were collected following natural spawnings either in 1 3 E3 medium
(286 mg/l NaCl, 13 mg/l KCl, 48 mg/l CaCl2$2H2O, 40 mg/l MgSO4, 0.01%
methylene blue) or 2 3 PTU (1 3 E3 medium, 30.4 mg/l phenylthiourea) and
allowed to develop at 28.5C.
Zebrafish Phenotype Screen and Additional Drug Treatments
Embryos were periodically checked for death and developmental delay before
treatment. At 7 hpf, embryos were arrayed in 96-well plates at one embryo/
well. Sample compounds were then added to the desired concentration,
with DMSO as control. DMSO was kept at 0.5% of the total assay volume.
Embryos were examined visually for viable and nonviable phenotypes with a
dissecting microscope at 24 hr posttreatment (hpt). Embryos were photo-
graphed live with an Olympus DP71 digital camera. All experiments were
repeated at least twice, in duplicate.
Compounds used in the screen were prepared in DMSO either as 10 mM or
5 mg/ml stocks. Further dilutions were carried out in DMSO. The Spectrum
Collection library was purchased from MicroSource Discovery Systems753–763, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 761
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(San Diego, CA). The chemistry andmarine natural product libraries are propri-
etary to the University of Utah.
For copper prevention experiments, embryos were treated with kalihinol
compounds at 5 hpf. Copper chloride (CuCl2$2H2O), calcium chloride
(CaCl2) or zinc acetate (ZnOAc2) was added 2 hr later at 5 or 10 mM final con-
centration, with embryo water as control. Phenotype suppression was evalu-
ated 24 hr after treatment with CuCl2.
For kalihinol rescue experiments, embryos were treated with 5 uM CuCl2 at
5 hpf. Trientine$2HCl (T-HCl) or kalihinol F was added 2 hr later at 10 mM or
5 mg/ml final concentration, with DMSO as control. Phenotype rescue was
evaluated 72 hpt with copper chelators.
In Situ Hybridization
In situ hybridizations were performed as previously described using digoxige-
nin-labeled riboprobes for ntl (no tail), myod (myogenic differentiation 1), hnf6
(hepatocyte nuclear factor 6), hbae1 (hemoglobin alpha embryonic-1), hbbe1
(hemoglobin beta embryonic-2), hbbe3 (hemoglobin beta embryonic-3),
alas2 (d-aminolevulinate synthetase 2), atoh7 (atonal homolog 7), col8a1a
(collagen type VIII, alpha 1a), col9a1 (collagen type IX, alpha 1), fabp7a (fatty
acid binding protein 7), crx (cone-rod homoebox), and tfa (transferrin-a)
(Nadauld et al., 2004).
o-Dianisidine Staining
o-Dianisidine staining was performed as previously described (Mendelsohn
et al., 2006). The embryos were then fixed with 8% paraformaldehyde/2 3
sucrose buffer at room temperature for 2 hr or overnight at 4C.
RNA Sequencing and Data Analyses
RNA was isolated from embryos treated with kalihinol F or DMSO at 32 hpf
using the RNeasy kit (QIAGEN). Quadruplicate biologic replica samples were
prepared and sequenced using Illumina HiSeq 2000 (Illumina). Raw data
were aligned using Novoalign (Novocraft) against the Zv9 genome build con-
taining known and theoretical splice junctions from Ensembl transcript anno-
tation. After converting splice junction matches to genomic coordinates, the
OverDispersedRegionScanSeqs (Useq) was used to identify differentially
expressed genes using an estimated FDR of 10% and 2-fold difference. GO
term analysis was performed using GoMiner (discover.nci.nih.gov/gominer).
BCA Assay
Bicinchoninic acid (BCA) assay was performed according to the manufac-
turer’s instructions with minor modifications (Pierce, Thermo Scientific).
EDTA, T-HCl, b-aminopropionitrile (b-APN), or kalihinol F was added to
CuCl2 in 0, 0.5, 1, and 2 molar ratios. The resulting solutions were incubated
at room temperature for 30 min to allow copper chelation to proceed and
then incubated at 37C for 15 min after the addition of bicinchoninic acid
and BSA. Samples were read on the spectrophotometer at 562 nm.
NMR Analysis
NMR experiments were carried out on a Varian INOVA 500 MHz spectrometer
with a 3mmNalorac MDBGprobe. Kalihinol F and pulcherrimol were each dis-
solved in DMSO-d6 (240 ml, 11 mM) and were titrated using 26 mM CuCl2 in
D2O. b-penicillamine was dissolved in DMSO-d6 (240 ml, 18 mM) and was
titrated using 48 mM CuCl2 in D2O.
1H NMR spectra were recorded after
each titration step with mixing at a sample temperature of 298 K. For each
spectrum, 16,384 data points were acquired (acquisition time 2.05 s) with a
spectral width of 8,000 Hz. Spectra were Fourier-transformed directly with
no window functions applied.
Yeast Culture and Drug Treatments
Wild-type W303 yeast cells were cultured in liquid yeast peptone (YP)-glucose
at 30C overnight. Approximately 400 cells were spotted per well in 48-well
YP-agar plate prepared with 2%-glycerol-2% lactate as carbon source and
supplemented with kalihinol F, bathocuproine disulphonate, or DMSO as con-
trol. The culture plate was incubated at 30C and yeast cell growth inhibition
due to chelation of available copper in the media was monitored visually for
2 days. Final drug concentration was either 0.5 or 5 mg/ml for kalihinol F and
0.1 or 1 mM for BCS.762 Chemistry & Biology 20, 753–763, June 20, 2013 ª2013 ElsevierFor growth rescue experiments, YP-agar plates were additionally treated
with either 50 uM or equimolar copper sulfate (CuSO4) or iron chloride
(FeCl2) for kalihinol F- and BCS-containing wells, respectively.
Cell Culture and Drug Treatments
Human hepatocellular carcinoma (HepG2) was obtained from ATCC and was
cultured according to the manufacturer’s protocols. Cells were plated in
six-well plates, seeded at 500,000 cells/well on day 1, and then treated
with 80 mM CuCl2 or DMSO the following day. The cells were then rescued
with 30 mg/ml kalihinol F or 160 mM T-HCl 1 hr later and incubated at 37C
for 24 hr.
Quantitative RT-PCR
RNA from cell lysates was isolated using the RNeasy kit (QIAGEN). cDNA
was synthesized from 4 mg of total RNA using Superscript III (Invitrogen).
When possible, intron-spanning primers were designed using the Universal
ProbeLibrary Assay Design Center (Roche Applied Science). A complete list
of primer sets is provided in Table S3.
PCR master mix was prepared with the LightCycler 480 Probes Master kit
and Universal ProbeLibrary probes according to the manufacturer’s protocols
(Roche Applied Science). PCR was performed in quadruplicate using the
LightCycler 480 System (Roche Applied Science) with 45 cycles of amplifica-
tion and annealing temperature of 60C. Fold change in gene expression was
measured by normalizing against 18S rRNA and comparing compound-
treated samples with DMSO-treated control.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and three tables and can
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